Nova Biomedical Adds CRP Test to Allegro® Analyzer

WALTHAM, Mass. - Oct. 7, 2020 - PRLog -- Nova Biomedical announces the addition of C-reactive protein (CRP) testing to its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter provides 11 clinically important tests to help physicians make therapeutic decisions and adjustments during the patient visit. The Allegro analyzer and this new CRP test are available in CE regulated countries. Allegro will be submitted to the U.S. FDA for CLIA waived use.

CRP is a protein made by the liver and is sent into the bloodstream in response to inflammation. Allegro's CRP test measures the amount of CRP in whole blood to detect inflammation due to acute conditions such as infection or to monitor chronic conditions including cardiovascular disease and autoimmune disease. CRP is just one of 11 tests for the Allegro platform, including glycated hemoglobin (HbA1c), Total Cholesterol, HDL Cholesterol, LDL Cholesterol Triglyceride, Glucose, Blood Creatinine, PT/INR, Urine Albumin and Urine Creatinine,

Allegro tests use capillary fingerstick samples for all tests, eliminating the need for venipuncture or a trained phlebotomist.  All tests use disposable test cartridges or strips. Allegro's quick six to nine-minute cartridge test times, less than 30 second test strip times, and ability to measure two cartridges simultaneously provide rapid results immediately to the physician during the patient visit. Having immediate results during the patient visit simplifies workflow and reduces clinic follow-up calls, letters, and patient re-visits, and improves patient compliance with care plans.

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova's BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Brazil.